Menevit Study: Menevit Anti-Oxidant Therapy for the Treatment of Male Infertility
Infertility, Male, Oxidative Stress
About this trial
This is an interventional treatment trial for Infertility, Male focused on measuring Male infertility, sperm, pregnancy, IVF (in vitro fertilisation), oxidative stress, free radicals, DNA damage
Eligibility Criteria
Inclusion Criteria: Evidence of oxidative stress to sperm on LPO-586 assay or poor HOST result or clinical evidence for oxidative stress (heavy smoker, varicocele, poor motility in the abscence of anti-sperm antibodies etc) Evidence of significant sperm DNA damage (25% or more DNA fragmentation as assessed by Tunel assay). Female partner willing to undergo IVF treatment within 3 months of starting Menevit trial Exclusion Criteria: Female partner 40 years of age or older at trial entry. Significantly reduced ovarian reserve in female partner (day 3-5 FSH > 10 iu/L if no prior IVF cycle or less than 5 oocytes on a prior IVF cycle. Sperm count below 0.5 million per ml (impossible to conduct all sperm function assays
Sites / Locations
- Repromed